Alcami, a contract development and manufacturing organisation (CDMO), announced on Tuesday that it has completed Phase II of its cGMP biostorage facility situated in Amherst, New Hampshire.
The company's 104,000 square feet area is now completely operational and supports various cGMP storage requirements. The whole site covers a total area of 160,000 square feet.
The company is planning to complete phase III in the first quarter of 2023 and will add an additional 56,000 square feet of new capacity.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients